0001209191-22-060440.txt : 20221209
0001209191-22-060440.hdr.sgml : 20221209
20221209090153
ACCESSION NUMBER: 0001209191-22-060440
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221207
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Link David Charles
CENTRAL INDEX KEY: 0001889464
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39871
FILM NUMBER: 221453749
MAIL ADDRESS:
STREET 1: 2100 E 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001833214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 853899721
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
BUSINESS PHONE: 605-679-6980
MAIL ADDRESS:
STREET 1: 2100 EAST 54TH STREET NORTH
CITY: SIOUX FALLS
STATE: SD
ZIP: 57104
FORMER COMPANY:
FORMER CONFORMED NAME: Big Cypress Acquisition Corp.
DATE OF NAME CHANGE: 20201120
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-07
0
0001833214
SAB Biotherapeutics, Inc.
SABS
0001889464
Link David Charles
2100 E 54TH STREET NORTH
SIOUX FALLS
SD
57104
1
0
0
0
Common Stock
2022-12-07
4
A
0
41493
1.205
A
57313
D
Warrant (Common Stock)
1.08
2022-12-07
4
A
0
41493
A
2023-06-07
2027-12-07
Common Stock
41493
41493
D
On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.
The Reporting Person states that the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities other than those directly owned by the Reporting Person for the purpose of Section 16, or for any other purpose.
/s/ David Charles Link
2022-12-09